- Recently Played
- My Playlists
- Favourites
Your Music
No activties found
- Tracks 0
- Followers2
- Following3
- Male
- Social Links
- Bio
-
On January 31, 2014, reports of strokes, heart attacks, and deaths in men taking FDA-approved testosterone-replacement led the FDA to announce that it would be investigating the issue. In addition, an increase of 30% in deaths and heart attacks in older men has been reported. Injectable forms of testosterone can cause a lung problem called pulmonary oil microembolism (POME). Gynecomastia and breast tenderness may occur with high dosages of testosterone due to peripheral conversion of testosterone by aromatase into excessive amounts of the estrogen estradiol. Exogenous testosterone may cause suppression of spermatogenesis in men, leading to, in some cases, reversible infertility. In women, testosterone can produce hirsutism (excessive facial/body hair growth), deepening of the voice, and other signs of virilization. Adverse effects may also include minor side effects such as oily skin, acne, and seborrhea, as well as loss of scalp hair, which may be prevented or reduced with 5α-reductase inhibitors.
A total of 117 out of 130 hypogonadal men completed study procedures through Week 24 and were included in the evaluation of testosterone pharmacokinetics after the third AVEED injection. Eligible patients weighed at least 65 kg, were 18 years of age and older (mean age 54.2 years), and had a morning serum total testosterone concentration 2. Higher serum testosterone average concentrations (579 ± 101 ng/dL and 567± 155ng/dL) were observed in patients with BMIs 2 and 26 to 30 kg/m2, respectively. A higher serum testosterone average concentration (568 ± 139 ng/dL) was observed in 57 patients weighing 65 to 100 kg. Analysis of serum testosterone concentrations from 117 hypogonadal men in the 84-week clinical study of AVEED indicated that serum testosterone concentrations achieved were inversely correlated with the patient’s body weight.
Hypogonadism can be treated with testosterone replacement therapy. Over the 3 to 6-month course of the studies reviewed, testosterone therapy appeared safe and generally effective, and (ruling out prostate cancer) the authors found no justification to absolutely restrict its use in men with CHF. As of 2014update, a number of lawsuits are underway against manufacturers of testosterone, alleging a significantly increased rate of stroke and heart attack in elderly men who use testosterone supplementation.needs update
A study by Wittert et al. highlighted the efficacy of oral testosterone on body composition. Changes in bone mineral density, skeletal muscle mass, and fat mass while receiving oral testosterone therapy have been well acknowledged. In a recent open-label study conducted by Swerdloff et al., 221 male patients between years of age with consistent serum total T 27. Patients were selected using a similar criterion to the above study; 27 were given 80mg of testosterone undecanoate twice a day, while six were given placebos.|Most clinicians aim for mid‑normal total testosterone (often ~400–700 ng/dL), individualized to symptom control and side effects. For oral TU, plan regular blood pressure monitoring. The 2023 TRAVERSE trial in high‑risk men found testosterone was non‑inferior to placebo for major cardiac events over follow‑up, though there were slightly higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury. If hematocrit climbs, your clinician may lower the dose, split injections, switch formulations, or pause therapy. Intranasal testosterone (3 times daily) avoids transfer risk and allows quick on/off. Fixing these can improve or even normalize testosterone, and will make any therapy work better. You’re a candidate when you have both consistent low levels and symptoms.|These values are substantially longer than those of testosterone enanthate (which, in castor oil, has values of 4.5 days and 8.5 days, respectively). Testosterone undecanoate has a very long elimination half-life and mean residence time when given as a depot intramuscular injection. Testosterone undecanoate is a prodrug of testosterone and is an androgen and anabolic–androgenic steroid (AAS).|In addition to its medical use, testosterone undecanoate is used to improve physique and performance. However, it has advantages over other testosterone esters in that it can be taken by mouth and in that it has a far longer duration when given by injection. Along with testosterone enanthate, testosterone cypionate, and testosterone propionate, testosterone undecanoate is one of the most widely used testosterone esters. It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization and suitable for androgen replacement therapy. Food and Drug Administration, there are no true quantifiable benefits of taking testosterone supplements.|In their study, they were able to determine that testosterone replacement therapy for up to 16 years yielded a normalization of testosterone serum levels in all patients. The studies were then screened for possible therapy effects on serum hormone levels, body composition (including skeletal muscle mass and fat mass), libido, mood, and adverse effects; afterward, relevant data was extracted. The advent of readily available testosterone therapy has increased the importance of finding the most efficacious and cost-efficient treatment modality to approach these patients. Testosterone should be used cautiously with warfarin (Coumadin) because testosterone can reduce breakdown of warfarin, leading to increased warfarin blood levels and bleeding risk. In 2013, a study aimed to evaluate the efficacy of testosterone undecanoate therapy on bone mineral density (BMD) and biochemical markers of bone turnover in elderly males with osteoporosis and low serum testosterone levels. Side effects of testosterone undecanoate include symptoms of masculinization like acne, increased hair growth, voice changes, hypertension, elevated liver enzymes, hypertriglyceridemia, and increased sexual desire.|In addition, local levels of DHT in so-called androgenic (5α-reductase-expressing) tissues are also markedly reduced, and this can have a strong impact on certain effects of testosterone. 5α-Reductase inhibitors like finasteride and dutasteride can slightly increase circulating levels of testosterone by inhibiting its metabolism. It is recommended that physicians screen for prostate cancer with a digital rectal exam and prostate-specific antigen (PSA) level before starting therapy, and monitor PSA and hematocrit levels closely during therapy.|The United States Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone supplement have been established for low testosterone levels due to aging. They recommend yearly evaluation regarding possible improvement and, if none, to discontinue testosterone; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar. A 2020 guideline from the American College of Physicians supports the discussion of testosterone in adult men with age-related low levels of testosterone who have sexual dysfunction. The primary use of testosterone is the treatment of males with too little or no natural testosterone production, also termed male hypogonadism or hypoandrogenism (androgen deficiency). Serious side effects may include liver toxicity, heart disease, and behavioral changes. Common side effects of testosterone include acne, swelling, and breast enlargement in men.|In addition to the prevention of testosterone conversion into DHT, 5α-reductase inhibitors also prevent the formation of neurosteroids like 3α-androstanediol from testosterone, and this may have neuropsychiatric consequences in some men. For instance, growth of body and facial hair and penile growth induced by testosterone may be inhibited by 5α-reductase inhibitors, and this could be considered undesirable in the context of, for instance, puberty induction. Androgens like testosterone are teratogens and are known to cause fetal harm, such as producing virilization and ambiguous genitalia. Testosterone may accelerate pre-existing prostate cancer growth in individuals who have undergone androgen deprivation. The FDA now requires warnings in the drug labeling of all approved testosterone products regarding deep vein thrombosis and pulmonary embolism. Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT).}
In a separate study on injectable testosterone therapy by Schiavi et al., a significant increase in the frequency of ejaculation and sexual desire in those receiving IM testosterone versus placebo was discovered . In the previously mentioned study by Saad et al., several quality-of-life factors were recorded to show improvement, including blood pressure, lipid quantity, urinary function, erectile function, and even AMS (aging males' symptoms) scores. In the 32 hypogonadal men with quantitative computed tomography (QCT) measurements before treatment, multiple regression analysis revealed a significant association of BMD with serum levels of testosterone and with age. In a study by Behre et al., intramuscular substitution therapy was applied to 52 patients with 250mg testosterone enanthate, injected almost every three weeks. - https://itheadhunter.vn/jobs/companies/what-is-earthing-and-is-it-beneficial/
